Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 5,833 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) CEO Abraham Ceesay sold 5,833 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $25.19, for a total transaction of $146,933.27. Following the completion of the transaction, the chief executive officer directly owned 573,746 shares in the company, valued at approximately $14,452,661.74. This represents a 1.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Abraham Ceesay also recently made the following trade(s):

• On Monday, November 17th, Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock. The stock was sold at an average price of $25.20, for a total value of $128,091.60.
• On Wednesday, October 15th, Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock. The shares were sold at an average price of $25.81, for a total value of $131,192.23.
• On Wednesday, October 15th, Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock. The shares were sold at an average price of $25.81, for a total value of $150,549.73.
• On Wednesday, September 17th, Abraham Ceesay sold 35,585 shares of Rapport Therapeutics stock. The stock was sold at an average price of $26.32, for a total value of $936,597.20.
• On Wednesday, September 17th, Abraham Ceesay sold 40,835 shares of Rapport Therapeutics stock. The shares were sold at an average price of $26.32, for a total transaction of $1,074,777.20.

Rapport Therapeutics Stock Performance

Shares of RAPP stock traded up $0.21 on Tuesday, hitting $25.32. The company’s stock had a trading volume of 190,681 shares, compared to its average volume of 369,411. The stock’s 50 day moving average is $26.27 and its 200-day moving average is $17.79. Rapport Therapeutics, Inc. has a fifty-two week low of $6.43 and a fifty-two week high of $42.27. The company has a market capitalization of $1.21 billion, a PE ratio of -9.34 and a beta of 1.64.

Rapport Therapeutics (NASDAQ:RAPP) last announced its earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06. On average, research analysts forecast that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Institutional Trading of Rapport Therapeutics

Several large investors have recently bought and sold shares of RAPP. Baker BROS. Advisors LP raised its stake in Rapport Therapeutics by 181.2% during the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock worth $45,949,000 after acquiring an additional 997,000 shares in the last quarter. Vestal Point Capital LP bought a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at approximately $28,215,000. Polar Capital Holdings Plc bought a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at approximately $27,887,000. Capital International Investors increased its position in Rapport Therapeutics by 30.7% during the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after purchasing an additional 800,000 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Rapport Therapeutics by 265.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company’s stock valued at $26,500,000 after purchasing an additional 648,378 shares during the last quarter.

Analyst Upgrades and Downgrades

RAPP has been the subject of several analyst reports. Citizens Jmp lifted their price objective on Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. The Goldman Sachs Group raised Rapport Therapeutics to a “strong-buy” rating in a research note on Friday, September 12th. HC Wainwright upped their price objective on shares of Rapport Therapeutics from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, September 8th. Wall Street Zen raised shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rapport Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $46.50.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.